In human medicine, antiangiogenic agents have been employed in the treatment of different types of cancer, mainly based on the inhibition of pro-angiogenic tumor signaling pathways, particularly the VEGF/VEGFR axis [56]. This evidence concerns the gene KDR and cancer.